| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Kidney (Neoplasm)SunitinibGastrointestinal stromal cell tumor GISTBevacizumabSorafenibTemsirolimusPazopanibEverolimusVEGFPegaptanibRanibizumab| 1 | 2008 | Sunitinib for advanced renal cell cancer. | 
| + | - | nl | Biologics 2(1):97-105 (2008) |
| 2 | 2007 | Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). |
| + | - | nl | Ther Clin Risk Manag 3(2):341-8 (2007) |
| 3 | 2010 | Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. |
| + | - | nl | Health Technol Assess 14(2):1-184, iii-iv (2010) |
| 4 | 2007 | A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. |
| + | - | nl | Ann Oncol 18 Suppl 10(-):x3-10 (2007) |
| 5 | 2007 | Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib. |
| + | - | nl | Ann Oncol 18 Suppl 10(-):x11-9 (2007) |
| 6 | 2007 | Sunitinib: bridging present and future cancer treatment. |
| + | - | nl | Ann Oncol 18 Suppl 6(-):vi31-4 (2007) |
| 7 | 2008 | Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. |
| + | - | nl | Cancer 113(6):1309-14 (2008) |
| 8 | 2007 | CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. |
| + | - | nl | Clin Cancer Res 13(13):3765-70 (2007) |
| 9 | 2007 | Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. |
| + | - | nl | Clin Cancer Res 13(5):1367-73 (2007) |
| 10 | 2010 | Targeted therapy for renal cell cancer: current perspectives. |
| + | - | nl | Discov Med 10(54):394-405 (2010) |
| 11 | 2007 | Vascular endothelial growth factor: biology and therapeutic applications. |
| + | - | nl | Int J Biochem Cell Biol 39(7-8):1349-57 (2007) |
| 12 | 2009 | Sorafenib and sunitinib. |
| + | - | nl | Oncologist 14(8):800-5 (2009) |
| 13 | 2010 | Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm. |
| + | - | nl | Isr Med Assoc J 12(10):628-32 (2010) |
